Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT05775042
PHASE2

Clinical Study of CM338 in the Treatment of Immunoglobulin A Nephropathy

Sponsor: Keymed Biosciences Co.Ltd

View on ClinicalTrials.gov

Summary

This study is a multicenter, randomized phase II clinical study to evaluate Efficacy and safety, while observing pharmacokinetic profiles, pharmacodynamic effects, and immunogenicity of CM338 in subjects with Immunoglobulin A(IgA) nephropathy.

Official title: A Phase II Clinical Study Evaluating the Efficacy and Safety of CM338 Injection in Subjects With Immunoglobulin A Nephropathy

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

70

Start Date

2023-05-08

Completion Date

2027-06-30

Last Updated

2024-10-15

Healthy Volunteers

No

Conditions

Interventions

BIOLOGICAL

CM338

CM338 injection

Locations (1)

Peking University First Hospital

Beijing, Beijing Municipality, China